|Bid||0.0000 x 800|
|Ask||0.0000 x 1000|
|Day's Range||0.4710 - 0.5258|
|52 Week Range||0.3720 - 8.5000|
|Beta (5Y Monthly)||1.77|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 02, 2022 - Nov 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.58|
Subscribe to Yahoo Finance Plus to view Fair Value for AGLE
Aeglea (AGLE) delivered earnings and revenue surprises of -3.85% and 55.99%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the second quarter ended June 30, 2022 and provided program updates.
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...